Related Experiment Video
Updated: Dec 25, 2025

Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles
Published on: October 19, 2015
Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles
Yaolin Xu1, Hui Wu1, Jing Huang1,2
1Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract:
Rationale: "Active targeting" based on the ligand-target affinity is a common strategy to precisely deliver nanoparticle (NP) imaging probes or drug carriers to the diseased tissue. However, such ligand-mediated active targeting inevitably takes place with prerequisite "passive targeting", driven by the enhanced permeability and retention (EPR) effect. Thus, the efficiency of active targeting in relation to off-targeted unbound NPs is of great importance in quantitative imaging of tumor biomarkers and delivery. With the notion that easy clearance of off-targeted uIONPs may lead to enhanced active targeting and tumor accumulation, we examined the NP size effect on "active targeting" of the transferrin receptor (TfR) using transferrin (Tf)-conjugated sub-5 nm (3 nm core) ultrafine iron oxide NPs (uIONPs) and larger IONPs (30 nm core). Methods: Green fluorescent dye (FITC)-labeled active targeting uIONPs (FITC-Tf-uIONPs) and red fluorescent dye (TRITC)-labeled passive targeting uIONPs (TRITC-uIONPs) were prepared. FITC-Tf-IONPs and TRITC-IONPs were used as comparison for the NP size effect. Multiphoton imaging, confocal fluorescence imaging, histological staining and computational analysis were applied to track different types of NPs in tumors at 1, 3 and 24 hours after co-injection of equal amounts of paired NPs, e.g., active targeting FITC-Tf-uIONPs and non-targeting TRITC-uIONPs, or FITC-Tf-IONPs and TRITC-IONPs into the same mice bearing 4T1 mouse mammary tumors. Results: Active targeting uIONPs exhibited an almost 6-fold higher level of tumor retention with deeper penetration comparing to non-targeting uIONPs at 24 hours after co-injection. However, accumulation of active targeting IONPs with a 30-nm core is only about 1.15-fold higher than non-targeting IONPs. The enhanced active targeting by uIONPs can be attributed to the size dependent clearance of unbound off-targeted NPs, as majority off-targeted uIONPs were readily cleared from the tumor by intravasation back into tumor blood vessels likely due to high interstitial pressure, even though they are not favorable for macrophage uptake. Conclusion: Ligand-mediated active targeting improves the delivery and accumulation of the sub-5 nm NPs. The improvement on active targeting is size-dependent and facilitated by NPs with sub-5 nm core sizes. Thus, sub-5 nm NPs may serve as favorable platforms for development of NP-based molecular imaging probes and targeted drug carriers.
Insights
Sub-5 nm nanoparticles enhance active targeting for improved tumor accumulation and penetration. This size-dependent effect is crucial for developing advanced molecular imaging probes and targeted drug delivery systems.
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Materials Science
Background:
- Active targeting using ligand-NP affinity is a strategy for precise delivery to diseased tissues.
- This strategy is often combined with passive targeting via the enhanced permeability and retention (EPR) effect.
- The efficiency of active targeting relative to off-targeted nanoparticles is critical for quantitative imaging and delivery.
Purpose of the Study:
- To investigate the effect of nanoparticle (NP) size on active targeting efficiency.
- To evaluate the transferrin receptor (TfR) targeting using transferrin (Tf)-conjugated sub-5 nm ultrafine iron oxide NPs (uIONPs) and larger IONPs.
- To determine if easy clearance of off-targeted uIONPs enhances active targeting and tumor accumulation.
Main Methods:
- Preparation of FITC-labeled active targeting uIONPs (FITC-Tf-uIONPs) and TRITC-labeled non-targeting uIONPs (TRITC-uIONPs).
- Comparison with larger FITC-Tf-IONPs and TRITC-IONPs to assess NP size effects.
- Co-injection of paired NPs into mice with 4T1 mammary tumors, followed by multiphoton and confocal imaging, histological staining, and computational analysis at 1, 3, and 24 hours.
Main Results:
- Active targeting uIONPs showed a ~6-fold higher tumor retention and deeper penetration than non-targeting uIONPs at 24 hours.
- Active targeting 30-nm IONPs exhibited only a 1.15-fold increase in accumulation compared to non-targeting IONPs.
- Enhanced active targeting with uIONPs is linked to size-dependent clearance of off-targeted NPs via intravasation, driven by high interstitial pressure.
Conclusions:
- Ligand-mediated active targeting significantly improves the delivery and accumulation of sub-5 nm nanoparticles.
- The enhancement in active targeting is dependent on nanoparticle size, favoring sub-5 nm core sizes.
- Sub-5 nm NPs represent promising platforms for developing advanced NP-based molecular imaging probes and targeted drug carriers.

